- Home
- IGMS vs CPHC Comparison
IGMS vs CPHC Comparison
Compare IGMS & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- CPHC
- Stock Information
- Founded
- IGMS 1993
- CPHC 1994
- Country
- IGMS United States
- CPHC United States
- Employees
- IGMS N/A
- CPHC N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- CPHC Services-Misc. Amusement & Recreation
- Sector
- IGMS Health Care
- CPHC Consumer Discretionary
- Exchange
- IGMS Nasdaq
- CPHC Nasdaq
- Market Cap
- IGMS 82.1M
- CPHC 89.8M
- IPO Year
- IGMS 2019
- CPHC 1994
- Fundamental
- Price
- IGMS $1.26
- CPHC $17.97
- Analyst Decision
- IGMS Hold
- CPHC
- Analyst Count
- IGMS 8
- CPHC 0
- Target Price
- IGMS $6.14
- CPHC N/A
- AVG Volume (30 Days)
- IGMS 172.4K
- CPHC 925.0
- Earning Date
- IGMS 05-13-2025
- CPHC 05-08-2025
- Dividend Yield
- IGMS N/A
- CPHC 1.55%
- EPS Growth
- IGMS N/A
- CPHC N/A
- EPS
- IGMS N/A
- CPHC 0.16
- Revenue
- IGMS $2,681,000.00
- CPHC $60,605,931.00
- Revenue This Year
- IGMS $124.45
- CPHC N/A
- Revenue Next Year
- IGMS $45.07
- CPHC N/A
- P/E Ratio
- IGMS N/A
- CPHC $110.78
- Revenue Growth
- IGMS 27.36
- CPHC N/A
- 52 Week Low
- IGMS $0.92
- CPHC $16.91
- 52 Week High
- IGMS $22.50
- CPHC $24.05
- Technical
- Relative Strength Index (RSI)
- IGMS 51.89
- CPHC 59.40
- Support Level
- IGMS $1.13
- CPHC $17.75
- Resistance Level
- IGMS $1.42
- CPHC $18.00
- Average True Range (ATR)
- IGMS 0.09
- CPHC 0.14
- MACD
- IGMS 0.01
- CPHC 0.10
- Stochastic Oscillator
- IGMS 52.94
- CPHC 95.65
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.